@ricky_banker
How are you doing?
Prof ZR appointment is to accelerate Nasdaq listing, not cfda.
Like many here we are frustrated with delays, and some have bailed out, 1%.
I have not let go of any.
If 10%, 20% or 30% of 137m (quoted on asx out of ~410m shares issued) had sold out, then i will be concerned .
Obviously 99% are prepared to wait.
I can only speak for myself coz i dont know anyone else financial situation.
As mentioned, i watched Xero sp movement from nzx IPO first day:
$1, 60c, 80c, drifting nowhere, but after *New Investors bought in, sp bounced from 80c to $1,2,3,4 to $5 (asx dual listing, when i bought it), the rest is history.
Today its A$55?
(Nasdaq will intro *New Investors to gmv =)
Nobody knows what gmv sp will do next 50 days, but i am willing to wait till after Nasdaq listing to see if my gritty wait will be handsomely rewarded.
I noticed you hold A2M and Xero.
Ask yourself why?
And if Gmv fits your investment criteria, then Hold;
if not you must reconsider your position. aimo.
Don't rely on what i say or anyone else on hc chatroom.
Everyone has a his/her reason/motive/agenda for posting.
Its not for me to question why.
Best wishes to all of us in next 50 business days.
I may go offscreen for next few weeks.
Dyor
- Forums
- ASX - By Stock
- GMV
- Ann: Quarterly Activities and Cashflow Report
Ann: Quarterly Activities and Cashflow Report, page-68
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online